Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.

MLA

Naranbhai, Vivek, et al. “Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.” Journal of Clinical Oncology, vol. 40, no. 1, Jan. 2022, pp. 12–23. EBSCOhost, https://doi.org/10.1200/JCO.21.01891.

APA

Naranbhai, V., Pernat, C. A., Gavralidis, A., St Denis, K. J., Lam, E. C., Spring, L. M., Isakoff, S. J., Farmer, J. R., Zubiri, L., Hobbs, G. S., How, J., Brunner, A. M., Fathi, A. T., Peterson, J. L., Sakhi, M., Hambelton, G., Denault, E. N., Mortensen, L. J., Perriello, L. A., & Bruno, M. N. (2022). Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. Journal of Clinical Oncology, 40(1), 12–23. https://doi.org/10.1200/JCO.21.01891

Chicago

Naranbhai, Vivek, Claire A Pernat, Alexander Gavralidis, Kerri J St Denis, Evan C Lam, Laura M Spring, Steven J Isakoff, et al. 2022. “Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.” Journal of Clinical Oncology 40 (1): 12–23. doi:10.1200/JCO.21.01891.